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from this chemical class is attributed to 
its ability to inhibit the bacterial enzyme 
transpeptidiase. This enzyme is required to 
form crosslinks between the sugars of the 
peptidoglycan layers, a mechanism that 
inevitably leads to the formation of a viable 
bacterial cell wall (2). 
As penicillin became widely used, a strain 
of Staphylococcus aureus was found to have 
conferred resistance to the antibiotic, 
and in 1959, methicillin, a synthetic 
variation of penicillin was introduced 
(as a member of the β-Lactam class) to 
ward off these infections. The longevity 
of its   effectiveness only lasted two years, 
and in 1961 the first case of Methicillin-
Resistant Staphylococcus aureus (MRSA) 
was described in the United Kingdom (3), 
with the first case reported in the United 
States in 1968 (4). In the years following 
its observance in the United States, studies 
involved with the isolation of MRSA in 
hospitals found that between 1975 and 
1980 there was an increase in the number 
of isolates amounting to 467% (4). 
Although infectious diseases, particularly 
those caused by bacterial microorganisms, 
are still among the top causes of mortality 
in the world, pharmaceutical support 
for the development of novel antibiotics 
against them continue to decline. 
Furthermore, when novel antibiotics 
are developed, they are introduced as 
modified derivatives of compounds already 
known to be effective (5). This practice 
has inadvertently become problematic; 
the lack of novel antibiotics to reduce 
natural selection and beneficial mutations 
in bacterial microorganisms has led to the 
emergence of antibiotic resistant organisms 
including MRSA, Vancomycin Resistant 
Enterococci (VRE), and Extreme Drug 
Resistant Tuberculosis (XDR-TB). Of 
these microorganisms, MRSA accounts 
for 1.9 million infections, 99,000 deaths, 
and health care costs amounting to over 5 
billion dollars annually, and is the number 
one health acquired infection in the United 
States (6). It is for these societal concerns 
that novel antibiotics are generated, but 
this is a trivial task. 
ABSTRACT
Implementation of antibiotics to treat 
bacterial infections began during World 
War II. Since then, a number of antibiotic 
resistance microorganisms have emerged, 
one of these being Methicillin Resistant 
Staphylococcus aureus (MRSA). This 
resistance can be accredited to multiple 
factors, but the greatest contributors are the 
similarity in the chemical composition of 
the commonly prescribed antibiotics used 
to treat MRSA and the improper use and 
disposal of these agents. MRSA is the most 
frequent health acquired infection in the 
United States and to combat this growing 
problem, we have developed a novel class 
of antibiotics derived from anthranilic 
acids that show antibacterial activity 
against MRSA. Our derivatives record a 
minimum inhibitory concentration (MIC) 
ranging from 2-64 µg/ml, however when 
in the presence of human serum protein 
(HSP) this value increases, decreasing 
their effectiveness. We have identified a 
component of HSP, albumin, that causes 
the increase in MIC, and have determined 
that intermolecular hydrogen bonding 
is the cause of this increase. Using this 
information we are currently synthesizing 
new derivatives with a low binding affinity 
for albumin, or when bound do not lose 
antibacterial activity.  
INTRODUCTION
In 1929 a microbiologist by the name 
of Alexander Flemming accidentally 
contaminated a microbial sample with the 
fungus Penicillium. After incubating the 
media for growth, he found that in areas 
where fungal growth was observed, bacterial 
growth was inhibited. By the year 1940 the 
antimicrobial properties of the fungus were 
investigated and then made available for 
medical use under the trade name penicillin 
(1). Penicillin functions as an exogenous 
metabolite belonging to the antibiotic family 
known as β-Lactams. Implemented into 
the health care system in the latter years of 
WWII, β-Lactams are still the most widely 
prescribed antibiotics in the world today. 
The effectiveness of the medications derived 
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In addition to the inherent costs associated 
with drug development, there are multiple 
intermolecular interactions that occur 
in vivo between drug and host that must 
be taken into account including drug 
toxicity, dosage, and excretion. A major 
contributor to these interactions is the 
well-studied protein component of human 
serum, albumin. Accounting for 65% of 
serum composition, albumin functions as a 
transporter for fatty acids and endogenous 
and exogenous metabolites (7). Research 
has shown that albumin drug binding 
occurs primarily at two “Sudlow” sites 
located in subdomains IIA (site 1) and IIIA 
(site II) of the protein; as a result, binding 
sequesters the compounds deeming them 
inactive (8)which is yet another  deterrent 
in developing novel drugs. However, as 
the advent of MRSA and other resistant 
microorganisms have emerged, the demand 
for new antibacterial reagents has caught 
the interest of pharmaceutical companies 
once again.  
In contribution to this increased interest, 
our research group has developed a novel 
class of antibiotics derived from anthranilic 
acids. Our class varies in effectiveness with 
many compounds showing antibacterial 
activity in vitro at a minimum inhibitory 
concentration (MIC) ranging between 
2-64 µg/ml; however, when in the presence 
of human serum protein (HSP) this value 
increases, decreasing their antibacterial 
activity. We have targeted albumin as the 
probable protein target responsible for 
this inactivating interaction. Our research 
group hopes to verify the role of albumin 
in the sequestration and inactivation of 
our novel antibiotics using computational 
biology software. By deducing if and how 
our compounds bind to albumin, we 
hope to use this information to develop 
derivatives with a lower binding affinity 
for HSP, or when bound do not lose 
antibacterial activity. If successful, the 
engenderment of such derivatives will 
add to the treatment options available 
to combat bacterial infections including 
MRSA, reducing antibiotic resistance 
and the costs associated with treatments 
currently administered. 
METHODS
Antibacterial activity determination. 
Twenty two novel antibiotics were 
generated to test for antibacterial activity.  
The anthranilic acid derivatives were 
dissolved at .01g each in 0.2 ml DMSO 
and 0.8 ml of 0.1 molar KOH equating 
to a final concentration of 10µg/ml. Using 
Staphylococcus aureus and Escherichia coli, 
the effectiveness of the compounds were 
analyzed for antimicrobial activity by 
employing the Kirby-Bauer disk diffusion 
method (CLSI; 9, 10). Ten microliters of 
each test compound was added to the 6 
mm sterile disks, followed by incubation 
at 35.7°C for 18-24 hours to stimulate 
bacterial growth. Our standard derivative, 
GV-2 (Fig. 1) was used as a positive control 
and was added at the same volume and 
concentration. After incubation, the agar 
plates were inspected and the zones of 
inhibition were measured. For each active 
compound, the minimum inhibitory 
concentration (MIC) was determined 
using standard microdilution protocol as 
prescribed by the Clinical and Laboratory 
Standards Institute (CLSI; 9, 10). 
Albumin binding. Any compound with 
an MIC ≤ 64µg/ml was tested in a second 
MIC assay with the addition of 10% 
HSP to determine if serum inactivation 
was observed. To assess albumin binding, 
bovine serum albumin (BSA) was prepared 
at 20%, 10%, and 5% concentrations 
(final concentrations 2%, 1%, .05%) in 
autoclaved 18 M Ohms dH2O solvent and 
was substituted for HSP in the dilution 
series using our standard test compound 
GV-2.  BSA was used for the analysis based 
on a 76.36% sequence alignment between 
the BSA protein structure and Human 
Serum Albumin (HSA).  
In order to determine whether our 
compounds were binding to albumin, the 
online docking server at http://swissdock.
ch was used. SwissDock is a free web service 
that determines the most probable binding 
interactions taking place between a target 
protein and ligand based on the EADock 
DSS algorithm (11). Only three steps are 
required to start a docking assay: 1) users 
define a target protein, 2) a ligand is selected 
from the comprehensive list supplied or 
from one that has been uploaded by the 
user, and 3) the docking parameters are 
set (11). The target protein for our assay, 
albumin (PDB: 2BXN), was obtained from 
the RCSB Protein Data Bank.  
To ensure a representative simulation, 
SwissDock runs a thorough check on the 
target protein and ligand(s) before running 
an assay (11). During this investigation, 
if any aspect of the protein structure is 
incomplete or defective and if the topology 
and tautomeric form of the ligand is 
incorrect, the assay is rejected (4, 11).  The 
albumin structure we selected was found 
to have 39 missing residues (http://www.
rcsb.or/pdb/files/2BXN.pdb). To correct 
this issue, the structure was patched 
using the Visual Molecular Dynamic 
software package. We generated our ligand 
(GV-2) using the Avogadro interface to 
ensure that the ligand met the criteria for 
the simulation. After completing these 
manipulations, albumin and GV-2 were 
uploaded into SwissDock and was accepted 
for the assay. The docking parameters were 
set to an accurate screening of the entire 
protein with a flexibility range within 3Å 
of any atom of the ligand in its reference 
binding mode. 
RESULTS
Of the 22 compounds that were 
synthesized, 13.6% showed antibacterial 
activity against Staphylococcus aureus 
(Table 1). Of those that showed activity, 
compound KU1-1-A had the greatest 
efficiency with a MIC equating to 16µg/
ml. A secondary screening for antibacterial 
activity completed in 10% human serum 
protein on compounds with a MIC ≤ 
64µg/ml showed an increase in the initial 
MIC recorded (Table 1). The results 
from the BSA MIC assay demonstrated 
that GV-2 did bind to albumin and its 
inactivation was concentration dependent 
upon the protein (Table 2). Thereafter, 
HSA was obtained from Sigma Aldrich 
and a MIC assay conducted using HSA 
demonstrated results that were consistent 
with that of BSA’s MIC results (Table 2). 
After this determination had been made, 
and the GV-2/albumin targets were 
uploaded into the SwissDock web interface, 
the output file of the binding interactions 
between GV-2 and albumin was visualized 
using Chimera 1.8 (12), which verified 
binding was occurring (Fig. 2). Binding 
interactions were considered significant if 
the interactions between atoms of GV-2 
and the molecules of albumin were within 
2 Å. Based upon this criterion, analysis 
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showed that the binding mode for the 
interactions between GV-2 and albumin is 
primarily due to intermolecular hydrogen 
bonding (Fig. 2) between the carboxylic 
acid functional group of the aromatic 
ring and the side chain residues spanning 
albumin in the region associated with both 
drug site I and II, with more interactions 
occurring within drug site II (Table 3).
After analyzing the binding data, it was 
proposed that coupling GV-2 would lead 
to a compound that was not inactivated 
in vivo. The theory was that coupled 
derivative would bind albumin while 
leaving the other end free and active, 
assuming a second albumin protein 
molecule was unable to bond the free 
end due to unfavorable electrostatic 
interactions. Five compounds meeting this 
structural proposition were synthesized by 
varying the chain length in the aliphatic 
region of GV-2, which was then coupled to 
another molecule of the same makeup (Fig. 
3). The results of the disk diffusion assay 
did not uphold the proposition in that no 
antibacterial activity was observed. 
DISCUSSION 
It is well documented that binding to HSA 
controls the free, active concentration of 
a drug, provides a repository for a long 
duration of action, and ultimately affects 
drug absorption, metabolism, distribution 
and excretion (8).  At one time these 
interactions were a major deterrent in 
generating novel drugs because of the 
unknown role of albumin on drug binding; 
however, the advancements that have been 
made in bioinformatics has revealed the 
mechanisms of action for albumin binding 
and in effect has increased pharmaceutical 
interests. With the information obtained 
from such molecular investigations, drug 
developers have been able to exploit 
albumin’s high binding affinity for anionic 
and hydrophobic fatty acid compounds. 
This has led to the anchoring of novel 
pharmaceuticals to albumin binding 
molecules utilizing the protein’s carrier 
capabilities and also to effective dosage 
schedules empirically devised for highly 
albumin – bound drugs (8).
The bioinformatics approach we have 
added to our study has also provided our 
team with some insightful information. 
Research conducted in our lab in the 
years preceding this investigation has 
shown that removal of the carboxylic 
acid functional group on the anthranilic 
core deems the synthesized derivatives 
inactive - results aligning with the 
information obtained from the binding 
analysis conducted in this study. Further 
analysis of the drug site for which GV-2 
binding was most favorable was also of 
importance; the hydrophobicity of the 
binding cavity and the positively charged 
pocket entrance creates an environment 
that is attractive to the anionic, fatty acid 
chemical makeup of GV-2 and most of 
our derivatives. This information was 
unknown and with its revelation our team 
is synthesizing derivatives by modifying the 
hydrophobicity and hydrophilicity of GV-2 
in an effort to create derivatives with a 
decreased binding affinity for HSP or when 
bound that do not lose its antibacterial 
activity. Although the five compounds we 
have synthesized reflecting the change  did 
not show any antibacterial activity, we 
believe the reason to be because they were 
not in concordance with the weight limit 
of antibacterial compounds prescribed by 
Lipinski’s rule of five, and we are currently 
making modifications so that these criteria 
are met. 
In contrast to the positive information 
provided by the protein docking assay the 
SwissDock interface has its limitations. 
Due to the complexities associated with 
predicting the binding affinity between 
ligands and targets, SwissDock does 
not provide this type of data; without 
having such information, alternative 
intermolecular interactions that may be 
contributing to GV-2 inactivation, such 
as, Van Der Wall forces or ionic bonding 
has not been accounted for in this study. 
Furthermore, the interface predicts binding 
for one ligand at a time. This may not be 
a true representation of what is occurring 
in vivo due to albumin’s ability to bind 
more than one ligand simultaneously 
by exposing other putative binding sites 
within the protein.  Although these areas 
have not been addressed in this study, 
these limitations do not negate the results 
obtained in that many drug developers 
have found success using SwissDock and 
similar docking servers.
The implications of our research endeavors 
are far reaching. The amount of infections 
attributed to MRSA has seen a steady 
increase worldwide and is not only a 
common HAI but has also become a 
common community acquired infection 
as well. The decreasing availability of 
antibiotics once effective in treating MRSA 
increases the potential for more deadly 
encounters with the superbug. Modifying 
our class of compounds so that they do not 
lose antibacterial activity in vivo, would 
allow their implementation into the health 
care system, which will effectively decrease 
morbidity and the amount of money spent 
on treating infections caused by MRSA 
and other antibiotic resistant organisms 
worldwide.
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FIGURES & DATA TABLES 
Fig. 1. Chemical structure of GV-2 (5-bromo-2-[(2E)-non-2-enoylamino] benzoic acid). 
Fig. 2. A depiction of GV-2 bound to human serum albumin between the carboxylic acid functional group 
and albumin side chain residues by means of intermolecular hydrogen bonding. 
Fig. 3. Proposition for new chemical derivative based on the coupling of GV-2
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Table 1. Antibacterial activity of GV-2 chemical derivatives against Staphylococcus aureus.  The zone of inhibition was measured on 
MH agar plates and the minimum inhibitory concentration was determined in the absence or presence of 10% human serum protein. 
Table 2. MIC of GV-2 in the presence of bovine and human serum albumin at 2%, 1% and 0.05% concentrations. Human serum 
protein was not subjected to testing at 2% and 1% concentrations because of our interest in comparing the lowest concentration of 
bovine serum albumin that produced a MIC < 256 µg/ml.
Table 3. Binding interactions occurring within 2 Å of albumin side chain residues and atoms of GV-2 as determined using 
SwissDock interface and Chimera 1.8.
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